VAM
ALXN

Visium Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Visium Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-9,055
Closed -$1.64M – 1258
2015
Q2 		$1.64M Buy
9,055
+4,725
+109% +$815K 0.02% 456
2015
Q1 		$750K Buy
+4,330
New +$784K 0.01% 568

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's ALXN Position: Q3 2015 in Review

Visium Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 9,055 shares — an estimated $1.64M sold.

Visium Asset Management first reported a position in ALXN in Q1 2015 and held it in 2 quarters. The position peaked at $1.64M in Q2 2015. 513 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

  • Visium Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Visium Asset Management sold 9,055 Alexion Pharmaceuticals shares in Q3 2015, an estimated $1.64M.
  • Visium Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Visium Asset Management's Alexion Pharmaceuticals position peaked at $1.64M in Q2 2015.
  • 513 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.